While approved for treatment of cancer-related hypercalcemia, gallium nitrate (Ganite®; GN) has displayed broad antitumor activity as a single agent in Phase 2 trials, particularly in patients (pts) with bladder disease, Hodgkin’s disease, and NHL who received GN by bolus or continuous IV infusion (CIVI). To establish the safety profile and clincial activity in a large cohort of patients with a wide variety of histologies, we conducted a Phase 2 study in pts with both T- and B-cell lymphoma who had relapsed from standard anti-lymphoma therapy.

Eligibility criteria included: relapsed NHL; ECOG PS ≤ 2; measurable disease; adequate renal and hepatic function. GN was administered by CIVI daily via ambulatory infusion pump x 7 days every 3 wks at 1 of 2 daily dose levels, 200 or 300 mg/m2/d. Evaluation for efficacy required treatment with ≥ 2 cycles; all treated pts were considered evaluable for safety. A total of 88 pts were accrued to the trial, 44 pts at each dose level. Pt characteristics included: median age, 61 yrs (range 19–83); median prior regimens, 5 (range 1–13); median prior drugs, 9 (range, 1–15); median prior rituximab regimens, 2 (range, 1–6); no. of pts with prior stem cell transplant, 25 (28%); no. of pts with prior radiation therapy, 29 (33%).

At the 300 mg/m2 dose level, 30 pts are evaluable for response. The ORR in this dose level was 30% (7% CR or uCR), including 3/12 pts with diffuse LCL (DLCL) (2 post-BMT), 3/11 with follicular lymphomas (1 post-BMT), 2/3 pts with mantle cell NHL (1 CR), 0/2 pts with SLL, and 1/2 pts with peripheral T-cell NHL (1 uCR). The results in the 200 mg/m2 dose level are preliminary and currently under evaluation.

Most frequent (> 10%) grade 3/4 adverse reactions (through July 2004) included: anemia (32%); hypocalcemia (19%) (occasionally requiring parenteral replacement with Ca++ and Mg++); dyspnea (15%); and hypotension (11%). Optic neuritis or visual disturbance occurred in 4 pts: 3 pts at the 300 mg/m2 dose level (after 2, 3 and 6 cycles, respectively) and 1 pt at the 200 mg/m2 dose level (after 7 cycles). All patients discontinued therapy as a consequence of this adverse event; two pts were treated with high-dose corticosteroids. All patients improved after discontinuation.

These results demonstrate that gallium nitrate is an active and well tolerated agent in a heavily pretreated population of patients with NHL and suggest that it may be particularly useful in patients who cannot tolerate myelosuppressive regimens.

Author notes

Corresponding author

Sign in via your Institution